Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison

被引:8
|
作者
Ward, Zoe [1 ]
Mafirakureva, Nyashadzaishe [1 ]
Stone, Jack [1 ]
Keevans, Mary [2 ]
Betts-Symonds, Graham [2 ,3 ]
Crowley, Desmond [4 ]
McHugh, Tina [5 ]
Avramovic, Gordana [6 ]
Lambert, John S. [5 ,6 ]
Vickerman, Peter [1 ]
机构
[1] Univ Bristol, Bristol, Avon, England
[2] Irish Prison Serv, Dublin, Ireland
[3] Irish Red Cross, Dublin, Ireland
[4] Irish Coll Gen Practitioners, Dublin, Ireland
[5] Mater Misericordiae Univ Hosp, Dublin, Ireland
[6] Univ Coll Dublin, Sch Med, Dublin, Ireland
基金
美国国家卫生研究院;
关键词
Ireland; People who inject drugs; Cost-effectiveness; Prison; Hepatitis C virus; Direct acting antivirals; INJECT DRUGS; PUBLIC-HEALTH; INFECTION; PEOPLE; HCV; METAANALYSIS; PREVENTION; SOFOSBUVIR; MORTALITY; IMPACT;
D O I
10.1016/j.drugpo.2021.103394
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: In Irish prisons, there is a high proportion of people who inject drugs (PWID; 26%) and a high prevalence of HCV (16%), making prison a high priority setting for HCV testing and treatment. We evaluate the cost-effectiveness of a mass HCV screening intervention in Mountjoy Prison, Dublin, compared to the standard-of-care of intermittent screening on committal. Methods: Primary cost data was collected from the intervention using an overall provider perspective. Standard-of-care (SOC) costs were estimated through interview. All costs were inflated to 2020 Euros. An HCV transmission and disease progression model among incarcerated and community PWID and ex-injectors was calibrated to the Dublin HCV epidemic, allowing inclusion of population-level health benefits. The model used intervention data, suggesting 419 individuals were screened, 50 HCV infections diagnosed and 32 individuals initiated treatment, to project the resulting costs and health benefits (quality adjusted life years or QALYs) over 50 years with 5% discounting. The incremental cost effectiveness ratio (ICER), cost per QALY gained, was estimated for the screening intervention compared to the standard-of-care. Probabilistic sensitivity analyses (PSA) determined the probability that the intervention was cost-effective compared to a willingness-to-pay threshold of (sic)30,000/QALY as used in Ireland. The ICER for 1- or 3-yearly mass screening in all Dublin prisons was also calculated. Results: The total direct costs of the intervention (not including treatment drug costs) was (sic)82,392, with most costs being due to staff(43%) and overhead or management costs (38%). Despite having little epidemiological impact due to the small numbers treated, over 50 years the incremental cost of the intervention was (sic)36,592 and 3.8 QALYs were gained, giving a mean ICER of (sic)9,552/QALY. The majority (84%) of PSA runs were below the willingness-to-pay threshold. Yearly mass screening had an ICER of (sic)2,729/QALY compared to SOC and gave a higher net monetary benefit ((sic)7,393,382) than screening every 3 years ((sic)6,252,816). Conclusion: Prison mass screening could be a cost-effective initiative for increasing testing and treatment of HCV in Ireland.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Cost-effectiveness of chronic hepatitis C screening and treatment
    Lee, Hye Won
    Lee, Hankil
    Kim, Beom Kyung
    Chang, Young
    Jang, Jae Young
    Kim, Do Young
    CLINICAL AND MOLECULAR HEPATOLOGY, 2022, 28 (02) : 164 - 173
  • [32] Cost-effectiveness of targeted screening for hepatitis C in The Netherlands
    Helsper, C. W.
    Borkent-Raven, B. A.
    De Wit, N. J.
    Van Essen, G. A.
    Bonten, M. J. M.
    Hoepelman, A. I. M.
    Janssen, M. P.
    De Wit, G. A.
    EPIDEMIOLOGY AND INFECTION, 2012, 140 (01): : 58 - 69
  • [33] A cost-effectiveness analysis of universal hepatitis C screening in all United States pregnancies
    Susich, Marguerite
    Hersh, Alyssa R.
    Greiner, Karen
    Chaiken, Sarina R.
    Caughey, Aaron B.
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2022, 35 (25): : 7381 - 7388
  • [34] Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan
    Mafirakureva, Nyashadzaishe
    Lim, Aaron G.
    Khalid, Gul Ghuttai
    Aslam, Khawar
    Campbell, Linda
    Zahid, Hassaan
    Van den Bergh, Rafael
    Falq, Gregoire
    Fortas, Camille
    Wailly, Yves
    Auat, Rosa
    Donchuk, Dmytro
    Loarec, Anne
    Coast, Joanna
    Vickerman, Peter
    Walker, Josephine G.
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (02) : 268 - 278
  • [35] Estimating the cost-effectiveness of daclatasvir plus sofosbuvir versus sofosbuvir plus ribavirin for patients with genotype 3 hepatitis C virus
    McEwan, Phil
    Webster, Samantha
    Ward, Thomas
    Brenner, Michael
    Kalsekar, Anupama
    Yuan, Yong
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15
  • [36] A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective
    Kim, Hye-Lin
    Kim, Kyung-Ah
    Choi, Gwang Hyun
    Jang, Eun Sun
    Ki, Moran
    Choi, Hwa Young
    Jeong, Sook-Hyang
    CLINICAL AND MOLECULAR HEPATOLOGY, 2022, 28 (01) : 91 - 104
  • [37] Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective - A qualitative exploration
    Crowley D.
    Van Hout M.C.
    Murphy C.
    Kelly E.
    Lambert J.S.
    Cullen W.
    Health & Justice, 6 (1)
  • [38] Cost-effectiveness of novel treatment of hepatitis C virus in Lebanese patients
    Soumana C. Nasser
    Hanine Mansour
    Tatiana Abi Nader
    Mirna Metni
    International Journal of Clinical Pharmacy, 2018, 40 : 693 - 699
  • [39] The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review
    Greenaway, Christina
    Makarenko, Iuliia
    Abou Chakra, Claire Nour
    Alabdulkarim, Balqis
    Christensen, Robin
    Palayew, Adam
    Anh Tran
    Staub, Lukas
    Pareek, Manish
    Meerpohl, Joerg J.
    Noori, Teymur
    Veldhuijzen, Irene
    Pottie, Kevin
    Castelli, Francesco
    Morton, Rachael L.
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2018, 15 (09)
  • [40] Cost-effectiveness of strategies for testing current hepatitis C virus infection
    Chapko, Michael K.
    Dufour, D. Robert
    Hatia, Rikita I.
    Drobeniuc, Jan
    Ward, John W.
    Teo, Chong-Gee
    HEPATOLOGY, 2015, 62 (05) : 1396 - 1404